1. Home
  2. CBIO vs SES Comparison

CBIO vs SES Comparison

Compare CBIO & SES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$16.10

Market Cap

471.3M

Sector

N/A

ML Signal

HOLD

Logo SES AI Corporation

SES

SES AI Corporation

HOLD

Current Price

$0.50

Market Cap

384.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
SES
Founded
2003
2012
Country
United States
United States
Employees
44
215
Industry
Auto Parts:O.E.M.
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
471.3M
384.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CBIO
SES
Price
$16.10
$0.50
Analyst Decision
Strong Buy
Buy
Analyst Count
6
1
Target Price
$26.67
$4.00
AVG Volume (30 Days)
491.9K
13.4M
Earning Date
04-29-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$53.90
Revenue Next Year
$279.20
$111.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.72
$0.53
52 Week High
$27.41
$3.73

Technical Indicators

Market Signals
Indicator
CBIO
SES
Relative Strength Index (RSI) 47.36 23.52
Support Level $14.69 N/A
Resistance Level $19.13 $1.01
Average True Range (ATR) 1.26 0.06
MACD 0.12 -0.01
Stochastic Oscillator 58.82 2.76

Price Performance

Historical Comparison
CBIO
SES

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About SES SES AI Corporation

SES AI Corp is a developer and manufacturer of rechargeable battery technologies and battery materials for Energy Storage Systems (ESS), Urban Air Mobility (UAM), drones, robotics, electric vehicles (EVs), and other applications. For Enery Storage Systems, the company supplies hardware and software solutions with battery health and safety management software powered by its AI-based platform, Molecular Universe. Additionally, it offers battery materials and high-energy and power-density Li-Metal and Li-ion cells, which can be used for drones, UAM, robotics, and EV applications. The company also offers access to Molecular Universe as a software product. Currently, it generates maximum revenue from the development of Li-ion and Li-Metal battery materials as per the client's specifications.

Share on Social Networks: